Germany Cancer Immunotherapy Market Size & Outlook
Germany cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
Germany cancer immunotherapy market highlights
- The Germany cancer immunotherapy market generated a revenue of USD 6,628.6 million in 2023 and is expected to reach USD 10,962.0 million by 2030.
- The Germany market is expected to grow at a CAGR of 7.5% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer immunotherapy market data book summary
| Market revenue in 2023 | USD 6,628.6 million |
| Market revenue in 2030 | USD 10,962.0 million |
| Growth rate | 7.5% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, Germany accounted for 5.3% of the global cancer immunotherapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany cancer immunotherapy market is projected to lead the regional market in terms of revenue in 2030.
- Spain is the fastest growing regional market in Europe and is projected to reach USD 6,410.1 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 65.71% in 2023. Horizon Databook has segmented the Germany cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
There are more than 1.4 million cancer patients in Germany, and the number continues to increase at an alarming rate. In order to reduce the cancer burden in the country, the German Cancer Consortium (DKTK) initiated the Cancer Immunotherapy (CI) Research Program.
The DKTK is a long-term initiative involving German Cancer Research Center (DKFZ), several German states, and the German Federal Ministry of Education and Research (BMBF). The organization's Joint Funding Program has supported more than 20 multicenter research studies and clinical trials since its inception in 2012.
The CI program intends to curb the growing cancer incidence using immunotherapy. Some of the key areas of focus in this program are combinatorial immunotherapy approaches, cellular therapeutics, tumor vaccines, and therapeutic antibodies. The R&D sector in oncology in Germany is likely to experience rapid growth, which is likely to propel the growth of cancer immunotherapy market over the forecast period.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Germany cancer immunotherapy market size, by product, 2018-2030 (US$M)
Germany Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
